Single-cell entropy as a selectable and inducible marker of stem-cell youth: a multi-track technical architecture for producing young autologous hematopoietic stem cells

The human body is a vast, self-repairing machine, but like any machine, its parts wear out over time. Nowhere is this wear and tear more critical than in the blood system. To keep us alive, a small pool of master cells in our bone marrow, known as hematopoietic stem cells, constantly divides to produce fresh red blood cells, white blood cells, and platelets. As we age, these master cells themselves begin to fail. They divide less often, make mistakes, and lose their ability to produce the diverse mix of blood cells the body needs. This decline is not just a matter of time passing; it is a biological shift where the cells become disordered and less coordinated. For decades, scientists have tried to reverse this process, often by taking a patient's own cells, trying to "reset" them to a younger state in a lab, and putting them back. However, these attempts have struggled with a fundamental problem: how do you know which cells are actually young and healthy, and how do you ensure they are safe to return to the body without causing cancer or immune rejection?

A new research proposal by Jaba Tqemaladze offers a fresh way to think about this problem. Instead of guessing which cells are young, the author suggests measuring a specific property called "single-cell entropy." In simple terms, entropy here is a measure of disorder. A healthy, young stem cell has a highly organized internal instruction manual, with its genes working in perfect sync. An aging cell, by contrast, becomes noisy and chaotic; its internal instructions get scrambled. The paper proposes that this disorder is not just a sign of aging, but a measurable trait that can be used to find the best cells. The core idea is to take a patient's own blood stem cells, measure their level of internal disorder, select the ones that are the most organized (the youngest), and return them to the bone marrow. If successful, this could replace the body's aging blood factory with a fresh, autologous (from the patient's own body) one, avoiding the need for dangerous immune-suppressing drugs usually required for transplants.

The paper does not claim to have already cured aging or produced a new drug. Instead, it lays out a detailed, step-by-step blueprint for a scientific program designed to test whether this idea can work. The author has structured the research into five different paths, or "tracks," that share common tools and safety checks. The primary path, called Track A, focuses on the most immediate and testable steps. It begins by trying to prove a specific link: that the more a stem cell has divided in the past, the more disordered its internal instructions become. If this link is confirmed, the next step is to develop a way to sort cells based on this disorder. The plan involves taking cells from donors of different ages, measuring their internal noise, and seeing if the cells from older people are indeed more chaotic. If a clear pattern emerges, researchers would then try to isolate the least chaotic cells from an older donor and put them back into a test environment to see if they can rebuild a healthy blood system.

Because simply sorting cells might not be enough if an older donor has very few "young" cells left, the proposal includes a second strategy: inducing youth. This involves using a technique called partial reprogramming, which briefly exposes cells to factors that reset their internal state without turning them into embryos. The goal here is to actively lower the disorder in the cells, making them functionally younger. The paper is very careful to distinguish between two types of disorder. One type relates to how much a cell can change into different types of tissue (potency), and the other relates to how much the cell has aged. The proposal argues that we must select for low aging disorder, not low potency, because we want cells that are young but still capable of doing their specific job of making blood.

The proposal also explores more speculative, high-risk paths for the future. One path, Track R, attempts to mimic nature's most powerful reset button: reproduction. It suggests taking a somatic cell, turning it into a germ cell, forcing it to go through a process similar to making sperm or eggs, and then fusing two of these to create a brand-new, young cell. This path is highly experimental and relies on overcoming significant biological hurdles, such as preventing genetic errors that occur during cell division. Another path, Track C, looks at a specific structure inside the cell called the centriole, which helps organize cell division. The idea is that removing this old structure and letting the cell build a new one might reset its age. A fourth path, Track T1, takes a different approach entirely: instead of removing and replacing cells, it tries to clean up the environment inside the bone marrow where the cells live, removing the "senescent" or dead cells that poison the neighborhood, hoping this allows the remaining old cells to recover.

Throughout this entire architecture, safety is the most important gate. The author emphasizes that any new cell product must pass rigorous checks before it could ever be considered for human use. These checks include ensuring the cells have not developed cancer-causing mutations, that they have the correct number of chromosomes, and that they will not trigger an immune attack when returned to the patient. A key part of the safety plan involves screening for new mutations in the cell's mitochondria, the power plants of the cell, which can sometimes cause the body to reject even its own modified cells. The proposal includes a system to detect these mutations and reject any cell product that shows signs of danger.

The paper is written as a "Registered Report," a format where the scientific community agrees to the plan and the methods before any data is collected. This ensures that the researchers cannot change their goals or hide negative results later. The author admits that many of the steps, particularly the more complex ones involving reproduction-like processes, have never been done in humans and may fail. In fact, the plan is designed so that if a specific step fails, the researchers stop and report the failure, rather than trying to force a result. For example, if the link between cell division and disorder cannot be proven, the entire selection strategy would be abandoned, and the researchers would pivot to the simpler strategy of cleaning up the bone marrow environment.

Ultimately, this paper is a roadmap for a high-stakes scientific journey. It does not promise a miracle cure, but it offers a clear, logical path to test a bold hypothesis: that we can measure the age of a single cell, pick out the youngest ones, and use them to restore a failing blood system. By breaking the problem down into small, measurable steps and building in strict safety checks at every turn, the proposal aims to move the field of stem cell rejuvenation from vague concepts to concrete, testable science. If the central idea holds true, it could one day allow people to replace their aging blood cells with their own, rejuvenated versions, extending healthy life without the risks of immune rejection. Until the experiments are run, however, this remains a carefully constructed plan waiting for the real world to confirm or deny its possibilities.